Search

Your search keyword '"Parisi, Sarah"' showing total 175 results
Start Over Author "Parisi, Sarah" Language english
175 results on '"Parisi, Sarah"'

1. A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes

Author

Mongiorgi, Sara, De Stefano, Alessia, Ratti, Stefano, Indio, Valentina, Astolfi, Annalisa, Casalin, Irene, Pellagatti, Andrea, Paolini, Stefania, Parisi, Sarah, Cavo, Michele, Pession, Andrea, McCubrey, James A., Suh, Pann-Ghill, Manzoli, Lucia, Boultwood, Jacqueline, Finelli, Carlo, Cocco, Lucio, and Follo, Matilde Y.

Published
2023
Full Text
View/download PDF

2. Deciphering signaling pathways in hematopoietic stem cells: the molecular complexity of Myelodysplastic Syndromes (MDS) and leukemic progression

Author

Casalin, Irene, De Stefano, Alessia, Ceneri, Eleonora, Cappellini, Alessandra, Finelli, Carlo, Curti, Antonio, Paolini, Stefania, Parisi, Sarah, Zannoni, Letizia, Boultwood, Jacqueline, McCubrey, James A., Suh, Pann-Ghill, Ramazzotti, Giulia, Fiume, Roberta, Ratti, Stefano, Manzoli, Lucia, Cocco, Lucio, and Follo, Matilde Y.

Published
2024
Full Text
View/download PDF

5. Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients

Author

Marconi, Giovanni, De Polo, Stefano, Martinelli, Giovanni, Nanni, Jacopo, Bertamini, Luca, Talami, Annalisa, Olivi, Matteo, Ragaini, Simone, Abbenante, Maria Chiara, Sartor, Chiara, Ottaviani, Emanuela, Bochicchio, Maria Teresa, Parisi, Sarah, Fontana, Maria Chiara, Cristiano, Gianluca, Raffini, Maddalena, Baldazzi, Carmen, Testoni, Nicoletta, Bonifazi, Francesca, Paolini, Stefania, Curti, Antonio, Cavo, Michele, and Papayannidis, Cristina

Published
2021
Full Text
View/download PDF

6. Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes

Author

Follo, Matilde Y., Pellagatti, Andrea, Armstrong, Richard N., Ratti, Stefano, Mongiorgi, Sara, De Fanti, Sara, Bochicchio, Maria Teresa, Russo, Domenico, Gobbi, Marco, Miglino, Maurizio, Parisi, Sarah, Martinelli, Giovanni, Cavo, Michele, Luiselli, Donata, McCubrey, James A., Suh, Pann-Ghill, Manzoli, Lucia, Boultwood, Jacqueline, Finelli, Carlo, and Cocco, Lucio

Published
2019
Full Text
View/download PDF

8. Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response

Author

Iacobucci, Ilaria, Lonetti, Annalisa, Venturi, Claudia, Ferrari, Anna, Papayannidis, Cristina, Ottaviani, Emanuela, Abbenante, Maria Chiara, Paolini, Stefania, Bresciani, Paola, Potenza, Leonardo, Parisi, Sarah, Cattina, Federica, Soverini, Simona, Russo, Domenico, Luppi, Mario, and Martinelli, Giovanni

Published
2014
Full Text
View/download PDF

9. The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study.

Author

Marconi, Giovanni, Candoni, Anna, Di Nicola, Roberta, Sartor, Chiara, Parisi, Sarah, Abbenante, Mariachiara, Nanni, Jacopo, Cristiano, Gianluca, Zannoni, Letizia, Lazzarotto, Davide, Giannini, Benedetta, Baldazzi, Carmen, Bandini, Lorenza, Ottaviani, Emanuela, Testoni, Nicoletta, Bezzi, Chiara Di Giovanni, Abd-alatif, Rania, Ciotti, Giulia, Fanin, Renato, and Martinelli, Giovanni

Subjects
ACUTE myeloid leukemia, OLDER patients, OVERALL survival, PROGNOSIS, COMORBIDITY
Abstract

Background: In older patients with acute myeloid leukemia (AML), the definition of fitness, prognosis, and risk of death represents an open question. Methods: In the present study, we tested the impact on survival of disease-and patient-related parameters in a large cohort of elderly AML patients homogeneously assigned to treatment with hypomethylating agents (HMAs). Results: In 131 patients with a median age of 76 years, we confirmed that early response (<0.001) and biology-based risk classification (p = 0.003) can select patients with better-predicted survival. However, a full disease-oriented model had limitations in stratifying our patients, prompting us to investigate the impact of baseline comorbidities on overall survival basing on a comorbidity score. The albumin level (p = 0.001) and the presence of lung disease (p = 0.013) had a single-variable impact on prognosis. The baseline comorbidity burden was a powerful predictor of patients' frailty, correlating with increased incidence of adverse events, especially infections, and predicted overall survival (p < 0.001). Conclusion: The comorbidity burden may contribute to impact prognosis in addition to disease biology. While the therapeutic armamentarium of elderly AML is improving, a comprehensive approach that combines AML biology with tailored interventions to patients' frailty is likely to fully exploit the anti-leukemia potential of novel drugs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

11. Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

Author

Ghelli Luserna Di Rorà, Andrea, Beeharry, Neil, Imbrogno, Enrica, Ferrari, Anna, Robustelli, Valentina, Righi, Simona, Sabattini, Elena, Verga Falzacappa, Maria Vittoria, Ronchini, Chiara, Testoni, Nicoletta, Baldazzi, Carmen, Papayannidis, Cristina, Abbenante, Maria Chiara, Marconi, Giovanni, Paolini, Stefania, Parisi, Sarah, Sartor, Chiara, Fontana, Maria Chiara, De Matteis, Serena, Iacobucci, Ilaria, Pelicci, Pier Giuseppe, Cavo, Michele, Yen, Timothy J., and Martinelli, Giovanni

Published
2018
Full Text
View/download PDF

12. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.

Author

Meazza, Raffaella, Ruggeri, Loredana, Guolo, Fabio, Minetto, Paola, Canevali, Paolo, Loiacono, Fabrizio, Ciardelli, Sara, Bo, Alessandra, Luchetti, Silvia, Serio, Alberto, Zannoni, Letizia, Retière, Christelle, Colomar-Carando, Natalia, Parisi, Sarah, Curti, Antonio, Lemoli, Roberto M., and Pende, Daniela

Subjects
KILLER cells, IMMUNE response, ACUTE myeloid leukemia, IMMUNOTHERAPY
Published
2023
Full Text
View/download PDF

13. Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients

Author

Parisi,Sarah and Finelli,Carlo

Subjects
Journal of Blood Medicine
Abstract

Sarah Parisi,1 Carlo Finelli2 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Serà gnoli”, Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy; 2IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Serà gnoli”, Bologna, ItalyCorrespondence: Sarah Parisi Email sarah.parisi2@unibo.itAbstract: Iron chelation therapy (ICT) is an important tool in the treatment of transfusion-dependent lower-risk myelodysplastic syndrome (MDS) patients. ICT is effective in decreasing iron overload and consequently in limiting its detrimental effects on several organs, such as the heart, liver, and endocrine glands. Besides this effect, ICT also proved to be effective in improving peripheral cytopenia in a significant number of MDS patients, thus further increasing the clinical interest of this therapeutic tool. In the first part of the review, we will analyze the toxic effect of iron overload and its mechanism. Subsequently, we will revise the clinical role of ICT in various subsets of MDS patients (low, intermediate, and high risk MDS, patients who are candidates for allogeneic stem cell transplantation).Keywords: iron overload, myelodysplastic syndrome, iron chelation therapy, hepcidin

Published
2021

14. Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment.

Author

Sartor, Chiara, Arpinati, Mario, Chirumbolo, Gabriella, Dozza, Luca, Cristiano, Gianluca, Nanni, Jacopo, Marconi, Giovanni, Robustelli, Valentina, Vigliotta, Ilaria, Parisi, Sarah, Terragna, Carolina, Testoni, Nicoletta, Paolini, Stefania, Martinelli, Giovanni, Curti, Antonio, Cavo, Michele, and Papayannidis, Cristina

Subjects
BLAST injuries, LYMPHOBLASTIC leukemia, TREATMENT effectiveness, ACUTE leukemia, OVERALL survival
Abstract

Antigen‐directed target therapy for B‐cell acute lymphoblastic leukemia (B‐ALL) is now the standard of care for relapsed/refractory (R/R) disease. A comprehensive determination of the target itself is mandatory to aid physician's choice. We determined baseline Cluster of differentiation 22 (CD22) expression percentage and fluorescent intensity on lymphoblasts of 30 patients with R/R B‐ALL treated with anti‐CD22 immunoconjugate drug Inotuzumab Ozogamicin (INO) and analyzed the impact of both parameters on patient outcome. Most patients (24/30, 80%) had a high leukemic blast CD22‐positivity defined as ≥90%. We did not observe a benefit in terms of complete remission, overall survival (OS) and duration of response (DoR) for patients with CD22 ≥ 90% versus CD22 < 90%. Concerning CD22‐FI quartile analysis we appreciated a trend for superior response rates in higher quartiles (Q2‐Q4) compared to Q1 and a significant benefit in terms of OS and DoR for patients with higher CD22‐FI. INO demonstrates to be effective also in patients with lower CD22 expression, but therapeutical benefits are more evident in patients with higher CD22‐FI. The evaluation of both CD22 percentage and CD22‐FI of the leukemic blast may help physicians in therapeutic choices for R/R B‐ALL patients when multiple treatment options are available, although no CD22 expression threshold can currently be identified below which INO should be considered not effective. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents.

Author

Papayannidis, Cristina, Nanni, Jacopo, Cristiano, Gianluca, Marconi, Giovanni, Sartor, Chiara, Parisi, Sarah, Zannoni, Letizia, Saed, Rashed, Ottaviani, Emanuela, Bandini, Lorenza, Testoni, Nicoletta, Baldazzi, Carmen, Solli, Vincenza, Ricci, Paolo, Di Giovanni Bezzi, Chiara, Abd‐alatif, Rania, Stanzani, Marta, Paolini, Stefania, Cavo, Michele, and Curti, Antonio

Subjects
ACUTE myeloid leukemia, VENETOCLAX, COMORBIDITY, HOSPITAL care, TUMOR lysis syndrome, HOSPITAL patients
Abstract

Venetoclax (VEN) and hypomethylating agent (HMAs) regimens are emerging as the standard of care for unfit for chemotherapy acute myeloid leukemia (AML) patients, but the safety and feasibility of a total outpatient management have not been fully investigated. Fifty‐nine AML patients with active disease received VEN and HMAs. Nineteen out of 59 (32.2%) patients received the first cycle as inpatients, whereas 40/59 (67.8%) patients were treated in the outpatient setting. No significant differences were observed with regard to incidence of adverse events (AEs), including tumor lysis syndrome (TLS), and the 30‐day and 60‐day mortality was comparable. Notably, an infectious prophylaxis inspired to that adopted during intensive chemotherapy resulted in a low infection rate with a reduced bacterial infections incidence in out‐ versus hospitalized patients (p <.0001). The overall time of hospitalization was significantly shorter in patients who received a total outpatient treatment as compared to those who received the first cycle as inpatients (5.9 vs. 39.7 days, p <.0001). Despite the adopted differences in treatment management, the efficacy was similar. These data indicate that a total outpatient management of VEN and HMAs is feasible in AML patients without negatively impacting on treatment efficacy and may yield pharmacoeconomic and quality‐of‐life benefits. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

18. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia.

Author

Ravaioli, Federico, Marconi, Giovanni, Martinelli, Giovanni, Dajti, Elton, Sartor, Chiara, Abbenante, Maria Chiara, Alemanni, Luigina Vanessa, Nanni, Jacopo, Rossini, Benedetta, Parisi, Sarah, Colecchia, Luigi, Cristiano, Gianluca, Marasco, Giovanni, Vestito, Amanda, Paolini, Stefania, Bonifazi, Francesca, Curti, Antonio, Festi, Davide, Cavo, Michele, and Colecchia, Antonio

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, HEMATOLOGIC malignancies, LIVER, ULTRASONIC imaging
Abstract

In adult patients, acute lymphoblastic leukemia (ALL) is a rare hematological cancer with a cure rate below 50% and frequent relapses. With traditional therapies, patients with relapsed or refractory (R/R) ALL have a survival that may be measured in months; in these patients, inotuzumab ozogamicin (IO) is an effective therapy. IO was linked to increased risk of veno‐occlusive disease/sinusoid obstruction syndrome (VOD/SOS), liver injury, and various grade of liver‐related complications during clinical trials and real‐life settings; however, hepatologic monitoring protocol is not established in this population. In our institution, 21 patients who received IO (median of 6 doses of IO administered) for R/R ALL were prospectively followed for hepatologic surveillance, including clinical evaluation, ultrasonography, and liver stiffness measurement (LSM) biochemistry. After a median follow‐up of 17.2 months, two SOS events were reported (both after allogeneic transplant) as IO potentially related clinically relevant adverse event. Mild alterations were reported in almost the totality of patients and moderate‐severe liver biochemical alterations in a quarter of patients. Within biochemicals value, AST and ALP showed an augment related to IO administration. LSM linearly augmented for each IO course administered. Baseline LSM was related to liver‐related changes, especially with the severity of portal hypertension (PH)‐related complications. Pre‐transplant LSM was higher in patients receiving IO when compared with a control cohort. PH‐related complications were discovered in nearly 77% of patients, with clinically significant PH occurrence and development of ascites in 38% and 14%, respectively. This prospective experience constitutes the rationale to design a hepatologic monitoring program in patients receiving IO. LSM may be of pivotal importance in this program, constituting a rapid and effective screening that quantitatively correlates with liver alterations. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters.

Author

Parisi, Sarah, Ruggeri, Loredana, Dan, Elisa, Rizzi, Simonetta, Sinigaglia, Barbara, Ocadlikova, Darina, Bontadini, Andrea, Giudice, Valeria, Urbani, Elena, Ciardelli, Sara, Sartor, Chiara, Cristiano, Gianluca, Nanni, Jacopo, Zannoni, Letizia, Chirumbolo, Gabriella, Arpinati, Mario, Lewis, Russell E., Bonifazi, Francesca, Marconi, Giovanni, and Martinelli, Giovanni

Subjects
KILLER cells, ACUTE myeloid leukemia, STEM cell transplantation, CANCER remission, IMMUNOTHERAPY
Abstract

Recently, many reports were published supporting the clinical use of adoptively transferred natural killer (NK) cells as a therapeutic tool against cancer, including acute myeloid leukemia (AML). Our group demonstrated promising clinical response using adoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cells in AML patients. Moreover, the antileukemic effect was correlated with the dose of infused alloreactive NK cells ("functional NK cell dose"). Herein, we update the results of our previous study on a cohort of adult AML patients (median age at enrollment 64) in first morphological complete remission (CR), not eligible for allogeneic stem cell transplantation. After an extended median follow-up of 55.5 months, 8/16 evaluable patients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2 × 105/kg). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement.

Author

Cristiano, Gianluca, Nanni, Jacopo, Sartor, Chiara, Parisi, Sarah, Marconi, Giovanni, Barbato, Francesco, Arpinati, Mario, Bonifazi, Francesca, Curti, Antonio, Cavo, Michele, Paolini, Stefania, and Papayannidis, Cristina

Subjects
EXTRAMEDULLARY diseases, LYMPHOBLASTIC leukemia, ACUTE leukemia, T cells, HEMATOPOIETIC stem cell transplantation
Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is a rare entity in the adult acute leukemia setting. Translocation (9;22)(q34;q11) and BCR-ABL1 rearrangement are occasionally found in T-ALL and have been reported in no more than 100 cases in the literature (most of which are chronic myeloid leukemia blast crisis). Here, we report the remarkable effectiveness of third-generation tyrosine-kinase inhibitor ponatinib in obtaining hematological and metabolic remission, in a patient with Philadelphia chromosome-positive de novo T-ALL and outcomes of a therapeutic strategy containing chemotherapy intensification, nelarabine, and allogeneic hematopoietic stem cell transplantation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. A Chemo-Free Bridge-to-Transplant Strategy with Venetoclax and Azacitidine for NPM1-Mutated Acute Myeloid Leukemia in Molecular Failure

Author

Sartor, Chiara, Brunetti, Lorenzo, Audisio, Ernesta, Cignetti, Alessandro, Zannoni, Letizia, Cristiano, Gianluca, Nanni, Jacopo, Ottaviani, Emanuela, Bandini, Lorenza, Parisi, Sarah, Paolini, Stefania, Sciabolacci, Sofia, Cardinali, Valeria, Papayannidis, Cristina, Cavo, Michele, Martelli, Maria Paola, and Curti, Antonio

Published
2022
Full Text
View/download PDF

28. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.

Author

Papayannidis, Cristina, Sartor, Chiara, Dominietto, Alida, Zappone, Elisabetta, Arpinati, Mario, Marconi, Giovanni, Cristiano, Gianluca, Nanni, Jacopo, Parisi, Sarah, Barbato, Francesco, Paolini, Stefania, Soverini, Simona, Terragna, Carolina, Robustelli, Valentina, Testoni, Nicoletta, Chirumbolo, Gabriella, Curti, Antonio, Cavo, Michele, and Bonifazi, Francesca

Subjects
STEM cell transplantation, LYMPHOBLASTIC leukemia, ACUTE leukemia, LYMPHOCYTES, HEMATOPOIETIC stem cell transplantation
Abstract

Patients signed an informed consent form for IO and DLI therapy and, patients alive at the time of data collection, signed an informed consent form for personal data collection. None of the patients developed aGvHD after DLI, except the patient who switched to Blinatumomab therapy, in which a grade three aGvHD (liver) was detected, at 45 days from the end of 2 SP nd sp Blinatumomab cycle, 9 months from last DLI infusion and 16 months from the last IO course. Response was defined as CR for bone marrow (BM) blasts <= 5% and no evidence of extramedullary (EM) disease, evaluated with Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in PET positive patients pre-IO therapy. [Extracted from the article]

Published
2021
Full Text
View/download PDF

29. IDH1/2 Mutations Are Maintained in a Subset of Patients with Acute Myeloid Leukemia in Complete Remission and Do Not Correlate with Residual Disease

Author

Marconi, Giovanni, Bandini, Lorenza, Patuelli, Agnese, Sartor, Chiara, Parisi, Sarah, Nanni, Jacopo, Cristiano, Gianluca, Zannoni, Letizia, Simonetti, Giorgia, Bochicchio, Maria Teresa, Ottaviani, Emanuela, Martinelli, Giovanni, Paolini, Stefania, Papayannidis, Cristina, Cavo, Michele, and Curti, Antonio

Published
2021
Full Text
View/download PDF

31. Impact of Comorbidities on Prognosis of Elderly Patients with Acute Myeloid Leukemia Who Receive Hypomethylating Agents

Author

Marconi, Giovanni, Candoni, Anna, di Nicola, Roberta, Sartor, Chiara, Parisi, Sarah, Abbenante, Mariachiara, Nanni, Jacopo, Cristiano, Gianluca, Lazzarotto, Davide, Giannini, Maria Benedetta, Baldazzi, Carmen, Fontana, Maria Chiara, Bandini, Lorenza, Ottaviani, Emanuela, Testoni, Nicoletta, Di Giovanni Bezzi, Chiara, Abd-alatif, Rania, Fanin, Renato, Martinelli, Giovanni, Paolini, Stefania, Cavo, Michele, Papayannidis, Cristina, and Curti, Antonio

Published
2021
Full Text
View/download PDF

32. Specific chromosomic alterations confer therapy resistance in a cohort of 49 patients with newly diagnosed acute myeloid leukemia treated with intensive chemotherapy

Author

Papayannidis, Cristina, Fontana, Maria Chiara, Marconi, Giovanni, Guadagnuolo, Viviana, Simonetti, Giorgia, Padella, Antonella, Soverini, Simona, Paolini, Stefania, Abbenante, Maria Chiara, Parisi, Sarah, Sartor, Chiara, Lo Monaco, Silvia, Manfrini, Marco, Zuffa, Elisa, Franchini, Eugenia, Venturi, Claudia, Bochicchio, Maria Teresa, di Rora, Andrea Ghelli Luserna, Ottaviani, Emanuela, Martinelli, Giovanni, Papayannidis, Cristina, Fontana, MARIA CHIARA, Marconi, Giovanni, Guadagnuolo, Viviana, Simonetti, Giorgia, Padella, Antonella, Soverini, Simona, Paolini, Stefania, Abbenante, Mariachiara, Parisi, Sarah, Sartor, Chiara, LO MONACO, Silvia, Manfrini, Marco, Zuffa, Elisa, Franchini, Eugenia, Venturi, Claudia, Bochicchio, MARIA TERESA, GHELLI LUSERNA DI RORÀ, Andrea, Ottaviani, Emanuela, and Martinelli, Giovanni

Subjects
Chemotherapy
Published
2016

33. A Three-Genes Signature of Anti-Apoptotic Genes Showed Different Mechanisms in Preventing Apoptosis in Acute Myeloid Leukemia Cells and Could Provide an Useful Model to Establish the Proper BH3-Mimetich Drug or Combination

Author

Nanni, Jacopo, GIORGIA SIMONETTI, Marconi, Giovanni, Fontana, Maria Chiara, Bruno, Samantha, Papayannidis, Cristina, Padella, Antonella, Abbenante, Mariachiara, Lo Monaco, Silvia, Tenti, Elena, Sartor, Chiara, Parisi, Sarah, Martinelli, Giovanni, and Jacopo Nanni, Giorgia Simonetti, Giovanni Marconi, Maria Chiara Fontana, Samantha Bruno, Cristina Papayannidis, Antonella Padella, Mariachiara Abbenante, Silvia lo Monaco, Elena Tenti, Chiara Sartor, Sarah Parisi, Giovanni Martinelli

Subjects
Apoptosis, Acute Myeloid Leukemia
Published
2017

34. TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome

Author

Ferrari, Anna, Papayannidis, Cristina, Zuffa, Elisa, Baldazzi, Carmen, Padella, Antonella, Franchini, Eugenia, Iacobucci, Ilaria, Paolini, Stefania, Guadagnuolo, Viviana, Perricone, Margherita, Robustelli, Valentina, Venturi, Claudia, Abbenante, Maria Chiara, Parisi, Sarah, Sartor, Chiara, Volpato, Francesca, Cattina, Federica, Simonetti, Giorgia, Fontana, Maria Chiara, Bochicchio, Maria Teresa, Frabetti, Federica, Lani, Elisa, Mancuso, Katia, Zannetti, Beatrice, Luatti, Simona, Ottaviani, Emanuela, Testoni, Nicoletta, Martinelli Giovanni, Ferrari, Anna, Papayannidis, Cristina, Zuffa, Elisa, Baldazzi, Carmen, Padella, Antonella, Franchini, Eugenia, Iacobucci, Ilaria, Paolini, Stefania, Guadagnuolo, Viviana, Perricone, Margherita, Robustelli, Valentina, Venturi, Claudia, Abbenante, Mariachiara, Parisi, Sarah, Sartor, Chiara, Volpato, Francesca, Cattina, Federica, Simonetti, Giorgia, Fontana, MARIA CHIARA, Bochicchio, MARIA TERESA, Frabetti, Federica, Lani, Elisa, Mancuso, Katia, Zannetti, BEATRICE ANNA, Luatti, Simona, Ottaviani, Emanuela, Testoni, Nicoletta, and Martinelli, Giovanni

Subjects
Cariotipo complesso
Published
2015

35. Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome

Author

Papayannidis, Cristina, Ferrari, Anna, Paolini, Stefania, Baldazzi, Carmen, Sartor, Chiara, Abbenante, Maria Chiara, Parisi, Sarah, Volpato, Francesca, Iacobucci, Ilaria, Padella, Antonella, Guadagnuolo, Viviana, Perricone, Margherita, Robustelli, Valentina, Venturi, Claudia, Simonetti, Giorgia, Zuffa, Elisa, Franchini, Eugenia, Ottaviani, Emanuela, Testoni, Nicoletta, Martinelli, Giovanni, Papayannidis, Cristina, Ferrari, Anna, Paolini, Stefania, Baldazzi, Carmen, Sartor, Chiara, Abbenante, Mariachiara, Parisi, Sarah, Volpato, Francesca, Iacobucci, Ilaria, Padella, Antonella, Guadagnuolo, Viviana, Perricone, Margherita, Robustelli, Valentina, Venturi, Claudia, Simonetti, Giorgia, Zuffa, Elisa, Franchini, Eugenia, Ottaviani, Emanuela, Testoni, Nicoletta, and Martinelli, Giovanni

Subjects
TP53
Published
2015

36. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia.

Author

Marconi, Giovanni, Talami, Annalisa, Abbenante, Maria Chiara, Sartor, Chiara, Parisi, Sarah, Nanni, Jacopo, Bertamini, Luca, Ragaini, Simone, Olivi, Matteo, de Polo, Stefano, Cristiano, Gianluca, Fontana, Maria Chiara, Bochicchio, Maria Teresa, Ottaviani, Emanuela, Arpinati, Mario, Sessa, Mariarosaria, Baldazzi, Carmen, Caso, Lucia, Testoni, Nicoletta, and Baccarani, Michele

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, ETOPOSIDE, BONE marrow transplantation
Abstract

Introduction: Clinical response and chemosensitivity of relapse or refractory AML patients were evaluated after rescue and bridge‐to‐transplant MEC (mitoxantrone, etoposide, and cytarabine) regimen. Methods and Patients: Fifty‐five consecutive AML patients were treated with MEC from 2009 to 2018. Chemosensitivity was evaluated by WT1 quantification. Results: 27/55 patients (49.1%) had AML resistant to induction and 28/55 patients (50.9%) had AML relapse. 25/55 patients (45.5%) achieved a CR after one course of MEC, and 12 patients (21.8%) achieved WT1 negativity. In 12 patients, a second MEC was administered. Four out of 12 patients improved significantly their response with the 2nd MEC. MEC was an effective bridge to transplant, 32/55 patients (58.2%) received an allogenic stem cell transplant. Median overall survival (OS) from MEC was 455 days (95% CI 307‐602 days.); patient with WT1 negative CR had the best OS (P<.000). Conclusion: WT1 is a useful marker of chemosensitivity after MEC as rescue and bridge‐to‐transplant therapy. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

38. A Three-Gene Immune Signature Including IDO1, BIN1 and PLXNC1 Predicts Survival in Acute Myeloid Leukemia

Author

Ragaini, Simone, Wagner, Sarah, Marconi, Giovanni, Parisi, Sarah, Sartor, Chiara, Nanni, Jacopo, Cristiano, Gianluca, Talami, Annalisa, Olivi, Matteo, Ocadlikova, Darina, Ciciarello, Marilena, Corradi, Giulia, Ottaviani, Emanuela, Papayannidis, Cristina, Paolini, Stefania, Vadakekolathu, Jayakumar, Cavo, Michele, Rutella, Sergio, and Curti, Antonio

Published
2020
Full Text
View/download PDF

39. An IDO1-Related 3-Gene Signature Predicts Overall Survival in Intermediate-Risk Acute Myeloid Leukemia

Author

Ragaini, Simone, Wagner, Sarah, Marconi, Giovanni, Parisi, Sarah, Sartor, Chiara, Nanni, Jacopo, Cristiano, Gianluca, Talami, Annalisa, Olivi, Matteo, Ocadlikova, Darina, Ciciarello, Marilena, Corradi, Giulia, Ottaviani, Emanuela, Papayannidis, Cristina, Paolini, Stefania, Vadakekolathu, Jayakumar, Cavo, Michele, Rutella, Sergio, and Curti, Antonio

Published
2019
Full Text
View/download PDF

40. The Use of Venetoclax for Acute Myeloid Leukemia in a Real-Life Setting: A Multicenter National Experience

Author

Nanni, Jacopo, Gianfaldoni, Giacomo, Cristiano, Gianluca, Marconi, Giovanni, Piccini, Matteo, Grieco, Pietro, Sr., Pilerci, Sofia, Sr., Gottardi, Michele, Cerrano, Marco, Parisi, Sarah, Sartor, Chiara, Ottaviani, Emanuela, Baldini, Lorenza, Testoni, Nicoletta, Baldazzi, Carmen, Paolini, Stefania, Gherlinzoni, Filippo, Bosi, Alberto, Boccadoro, Mario, Cavo, Michele, Papayannidis, Cristina, and Curti, Antonio

Published
2019
Full Text
View/download PDF

41. Differential activation of nuclear inositide-dependent signalling pathways during erythropoiesis and myelopoiesis induced by lenalidomide and azacitidine in myelodysplastic syndromes (MDS)

Author

Mongiorgi, Sara, Follo, Matilde Y., Clissa, Cristina, Parisi, Sarah, Stanzani, Marta, Quaranta, Marilisa, Orsini, Ester, Martini, Desiree, and Finelli, Carlo

Subjects
hemic and lymphatic diseases, Nuclear Inositide Signalling, Erythroid Differentiation, Myeloid Differentiation
Abstract

Inositide-dependent signalling pathways regulated by phosphoinositide-specific phospholi- pase C (PI-PLC) beta1 have been demonstrated to play important roles in MDS pathogenesis and in cell differentiation (1). Moreover, the MDS therapy aims at inducing myeloid and/or erythroid differentiation of MDS stem cells. Indeed, azacitidine is a demethylating agent that can induce myeloid differentiation. On the other hand, lenalidomide may restore a normal erythropoiesis. The exact molecular mechanisms underlying the effect of azacitidine and lenalidomide in MDS cells are still unclear, although it is clear that these therapies regulate stem cell proliferation, differentiation and apoptosis (2). The combination of azacitidine and lenalidomide in MDS therapy is now under considera- tion, given the capability of both drugs to balance proliferation and differentiation processes (3). In this study we analyzed the molecular effect of this combination therapy on PI-PLC isoenzymes, not only studying PI-PLCbeta1, but also PI-PLCgamma1, that can be associated with erythropoiesis. We analyzed 44 patients diagnosed with high-risk MDS who were given azacitidine and lenalidomide. Given the limited number of cells, we quantified the expression of these molecules by Real-Time PCR analyses and immunocytochemical experiments. Moreover, we carried out cell cycle analyses and studied both PI-PLCbeta1 methylation status and the expression of Globin genes. In our case series, 28/44 patients were evaluable, with an overall response rate of 78.6% (22/28 cases). At a molecular level, a significant increase of PI-PLCbeta1 and/or PI-PLCgamma1 expression was associated with a favourable clinical response to the combination therapy. Responder cases also showed an increase of Beta-globin expression, hinting at a specific contri- bution of lenalidomide on erythroid activation, whilst the frequent demethylation of PI-PLCbeta1 promoter could be specifically linked to azacitidine. Taken together, our results show that the combination of azacitidine and lenalidomide can be important for activating PI-PLC isoenzymes, therefore regulating myeloid and erythroid dif- ferentiation in MDS cells., Italian Journal of Anatomy and Embryology, Vol. 120, No. 1 (Supplement) 2015

Published
2015
Full Text
View/download PDF

42. Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience

Author

Papayannidis, Cristina, Iacobucci, Ilaria, Abbenante, Mariachiara, Lonetti, Annalisa, Guadagnuolo, Viviana, Ferrrari, Anna, Ottaviani, Emanuela, Curti, Antonio, Paolini, Stefania, Parisi, Sarah, Clissa, Cristina, Baccarani, Michele, Martinelli, Giovanni, Papayannidis, Cristina, Iacobucci, Ilaria, Abbenante, Mariachiara, Lonetti, Annalisa, Guadagnuolo, Viviana, Ferrrari, Anna, Ottaviani, Emanuela, Curti, Antonio, Paolini, Stefania, Parisi, Sarah, Clissa, Cristina, Baccarani, Michele, and Martinelli, Giovanni

Subjects
Nelarabine, T-Acute Lymphoblastic Leukemia
Abstract

Background. Nelarabine (N) is approved for the treatment of T-ALL and T-LBL that have not responded to or has relapsed after treatment with at least 2 chemotherapy regimens. Aim. To evaluate safety profile and efficacy of N as savage therapy in 16 adult relapsed or refractory T-ALL or T-LBL. Methods. After obtaining an informed consent, 16 patients (median age 33 years, range 19-45, M/F = 13/3) affected by T-ALL (n=10) and T-LBL (n=6) received savage therapy with N (median cycle=1, range 1-3), administered at standard adult dosage (1500 mg/sqm on days 1, 3 and 5, every 21). Four patients were primary resistant to induction treatment, 7 patients were relapsed after two previous chemotherapy regimens (including allogeneic BMT in 4 cases and autologous SCT in 1 case); the remaining 6 patients had a molecular relapsed disease (MRD positive). Molecular characterization was performed, including NOTCH and WT-1 genes mutational status. GEP analysis, according to Ferrando A. stratification (Cancer Cell 2002), is still ongoing. Results. Currently, 12 out of 16 patients are evaluable, due to a too short follow up in the other 4 cases. Seven out of 12 patients obtained a complete remission (CR) (5 T-ALL 2 T-LBL);a partial remission (PR) was documented in 2 cases, with an overall response rate (ORR) of 75%. Median duration of CR was 10 weeks (range 2.8-54+). Among these, 2 out of 4 patients in molecular relapse reached a molecular CR and underwent an allogenic BMT (currently in CR after a median follow up of 12 months). Extra- hematological toxicity, not clearly related to the drug, occurred in 3 cases, determining, a complete and irreversible paraplegia, a condition of mental confusion, and a peripheral neuropathy, respectively. Conclusions. N showed a strong efficacy also in cases with low levels of residual disease, in addition to a good safety profile. Neurological toxicity needs to be strictly monitored. Acknowledgments. European LeukemiaNet, AIL, AIRC, Fondazione Del Monte di Bologna e Ravenna, FIRB 2006, PRIN 2008, Ateneo RFO grants, Project of integrated program (PIO), Programma di Ricerca Regione – Università 2007 – 2009.

Published
2011

43. Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience

Author

PAPAYANNIDIS, CRISTINA, Iacobucci, Ilaria, Soverini, Simona, Colarossi, Sabrina, Gnani, Alessandra, LONETTI, ANNALISA, Ferrari, Anna, Testoni, Nicoletta, AMABILE, MARILINA, Ottaviani, Emanuela, Maria Chiara Abbenante, Curti, Antonio, Paolini, Stefania, LAMA, BARBARA, CLISSA, CRISTINA, Parisi, Sarah, GUADAGNUOLO, VIVIANA, Baccarani, Michele, Martinelli, Giovanni, Papayannidis, Cristina, Iacobucci, Ilaria, Soverini, Simona, Colarossi, Sabrina, Gnani, Alessandra, Lonetti, Annalisa, Ferrari, Anna, Testoni, Nicoletta, Amabile, Marilina, Ottaviani, Emanuela, Maria Chiara Abbenante, Curti, Antonio, Paolini, Stefania, Lama, Barbara, Clissa, Cristina, Parisi, Sarah, Guadagnuolo, Viviana, Baccarani, Michele, and Martinelli, Giovanni

Subjects
acute lymphoblastic leukemia (ALL), hemic and lymphatic diseases
Abstract

Background. Approximately 30% of adult ALL patients are characterized by the presence of the Philadelphia (Ph) chromosome, which derives from a reciprocal translocation t(9;22)(q34;q11) and results in a chimeric BCR-ABL oncogene. The prognosis of this subset of patients treated with standard therapies, including multi-agent chemotherapy, Imatinib, and allogeneic stem cell transplantation, is still dismal, due to a high risk of relapse. Dasatinib and Nilotinb are second generation TKIs developed to overcome the problem of resistance to Imatinib in relapsed Ph+ leukemias. Design and Methods. We retrospectively evaluated the single center experience on therapy efficacy of Dasatinib, Nilotinib, and experimental third generation TKIs, administered as second or subsequent line of therapy on 25 relapsed Ph+ adult ALL patients. All patients were previously treated with Imatinib. The median age at time of diagnosis was 50 years (range 18-74), 17 patients were male and 8 female. Ten patients presented a BCR-ABL P190 fusion protein and corresponding fusion transcript, the remaining a BCR-ABL P210. Nineteen patients received Dasatinib, 2 patients Nilotinib and the remaining 4 patients were treated with third generation TKIs. Fourteen patients (56%) were in first relapse, and 7 (28%), 3 (12%) and 1 (4%) were in second, third and fourth relapse, respectively. A mutational analysis was performed in all the patients before TKIs (9 wild type, 16 mutated, including T315I) and at the time of subsequent relapse; gene expression profiling, SNPArray (6.0 Affymetrix chip), and Ikaros deletions were also analyzed. Results. 13 out of 25 patients (52%) obtained a haematological response (HR) (11 patients treated with Dasatinib, 1 patient with Nilotinib and 1 patient with a third generation experimental TKI). 10 patients obtained also a cytogenetic response (CyR) and 6 patients a molecular response (MolR). With a median follow up of 10.8 months (range 2-29 months), median duration of HR, CyR and MolR were 117 days (range 14-385 days); progression free survival were 162 days with Dasatinib and 91 days with Nilotinib. Overall survival was 25.8 months. Interestingly, in 6 out of 9 wild-type patients, treated with Dasatinib, the mutational analysis showed the emergence of T315I or F317I mutation at the time of relapse. Conclusion. Second and third generation TKIs represent a valid approach in relapsed Ph+ adult ALL patients; the subsequent relapse is often associated to the emergence of mutation, conferring resistance to TKIs.

Published
2010

44. RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML)

Author

Papayannidis, Cristina, Paolini, Stefania, Ottaviani, Emanuela, Salmi, Federica, Lama, Barbara, Curti, Antonio, Lacobucci, Ilaria, Parisi, Sarah, Clissa, Cristina, Piccaluga, Pier Paolo, Cilloni, Daniela, Saglio, Giuseppe, anna candoni, Morabito, Fortunato, Finelli, Carlo, Vianelli, Nicola, Raponi, Mitch, Serra, Massimo, Baccarani, Michele, Martinelli, Giovanni, and Cristina Papayannidis, Stefania Paolini, Emanuela Ottaviani, Federica Salmi, Barbara Lama, Antonio Curti, Ilaria Iacobucci, Sarah Parisi, Cristina Clissa, Pier Paolo Piccaluga, Daniela Cilloni, Giuseppe Saglio, Anna Candoni, Fortunato Morabito, Carlo Finelli, Nicola Vianelli, Mitch Raponi, Massimo Serra, Michele Baccarani, Giovanni Martinelli

Subjects
Tipifarnib, Bortezomib, Acute Myeloid Leukemia
Published
2014

45. Comparison of Two Different Therapeutic Regimens with Azacitidine and Lenalidomide (Combined versus Sequential) in Higher-Risk Myelodysplastic Syndromes. Update of Long-Term Results of a Randomized Phase II Multicenter Study

Author

Finelli, Carlo, Clissa, Cristina, Follo, Matilde Y, Parisi, Sarah, Fogli, Miriam, Mongiorgi, Sara, Capodanno, Isabella, Bosi, Costanza, Castagnari, Barbara, Candoni, Anna, Crugnola, Monica, Giannini, Maria Benedetta, Gobbi, Marco, Leonardi, Giovanna, Rigolin, Gian Matteo, Russo, Domenico, Tosi, Patrizia, Pellagatti, Andrea, Boultwood, Jacqueline, Cocco, Lucio, and Cavo, Michele

Published
2018
Full Text
View/download PDF

46. Negative Prognostic Relevance of a Specific 3-Gene Cluster in Myelodysplastic Syndromes during Azacitidine and Lenalidomide Therapy

Author

Follo, Matilde Y, Pellagatti, Andrea, Armstrong, Richard N, Ratti, Stefano, Mongiorgi, Sara, Astolfi, Annalisa, Indio, Valentina, Bochicchio, Maria Teresa, Clissa, Cristina, Russo, Domenico, Gobbi, Marco, Parisi, Sarah, Fogli, Miriam, Martinelli, Giovanni, Pession, Andrea, Cavo, Michele, Manzoli, Lucia, Cocco, Lucio, Boultwood, Jacqueline, and Finelli, Carlo

Published
2018
Full Text
View/download PDF

47. Mitoxantrone, Etoposide and Cytarabine (MEC) Can Induce Deep Complete Remission and Is an Effective Bridge Therapy to Allotransplantation (SCT) in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

Author

Marconi, Giovanni, Talami, Annalisa, Abbenante, Maria Chiara, Paolini, Stefania, Sartor, Chiara, Parisi, Sarah, de Polo, Stefano, Nanni, Jacopo, Bertamini, Luca, Ragaini, Simone, Olivi, Matteo, Fontana, Maria Chiara, Bochicchio, Maria Teresa, Ottaviani, Emanuela, Baldazzi, Carmen, Testoni, Nicoletta, Martinelli, Giovanni, Cavo, Michele, Papayannidis, Cristina, and Curti, Antonio

Published
2018
Full Text
View/download PDF

48. Biology of Acute Myeloid Leukemia (AML) with Monosomy of Chromosome 7 or Loss of 7q. a Study on 487 Patients Analyzed By Gene Expression Profile (GEP), Single Nucleotide Polymorphism (SNP) Arrays and Metabolomics

Author

Fontana, Maria Chiara, Olivi, Matteo, Marconi, Giovanni, Abbenante, Mariachiara, Fonzi, Eugenio, Paolini, Stefania, Sartor, Chiara, Parisi, Sarah, Bruno, Samantha, Pazzaglia, Martina, De Polo, Stefano, Nanni, Jacopo, Bertamini, Luca, Ragaini, Simone, Talami, Annalisa, Bochicchio, Maria Teresa, Ottaviani, Emanuela, Ferrari, Anna, Baldazzi, Carmen, Testoni, Nicoletta, Haferlach, Torsten, Kralovics, Robert, Milosevic Feenstra, Jelena D., Soverini, Simona, Martinelli, Giovanni, Curti, Antonio, Cavo, Michele, Papayannidis, Cristina, and Simonetti, Giorgia

Published
2018
Full Text
View/download PDF

49. Tyrosine Kinase Inhibitors (TKI) in Relapsed/Refractory (RR) Patients with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Confer Better Survival than Chemotherapy, Due to a Better Safety Profile

Author

Papayannidis, Cristina, Marconi, Giovanni, De Polo, Stefano, Ottaviani, Emanuela, Paolini, Stefania, Bochicchio, Maria Teresa, Nanni, Jacopo, Bertamini, Luca, Abbenante, Maria Chiara, Sartor, Chiara, Parisi, Sarah, Baldazzi, Carmen, Curti, Antonio, and Martinelli, Giovanni

Published
2018
Full Text
View/download PDF

50. Age, Disease Status before Blinatumomab, MRD Negativity Obtainment, and Bridge to Transplant Influence Outcome in Patients with B-ALL: A Single Center Experience

Author

Papayannidis, Cristina, Paolini, Stefania, Marconi, Giovanni, Nanni, Jacopo, Santoro, Alessandra, Robustelli, Valentina, Abbenante, Maria Chiara, Sartor, Chiara, Terragna, Carolina, Baldazzi, Carmen, Volpato, Francesca, Parisi, Sarah, Bertamini, Luca, Curti, Antonio, and Martinelli, Giovanni

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results